Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rhythm Biosciences Ltd, an Australian firm specializing in pioneering cancer diagnostic technologies, has successfully closed a shortfall offer related to their recent rights issue, raising a total of $2,745,416. The company expressed gratitude to both new and existing shareholders for their participation. This capital raise is aimed at advancing the development and distribution of their ColoSTAT® Test-Kit for early detection of colorectal cancer, which is based on significant research and has international patent protection.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges